The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Insights into a study on Mediterranean CD19 genetic variations & CAR-T efficacy
Osama Alsmadi, PhD, King Hussein Cancer Center, Amman, Jordan, discusses findings from a study evaluating the effects of Mediterranean CD19 genetic variants on the efficacy of CAR T-cell therapy. Dr Alsmadi highlights that a key residue at amino acid position 174, prevalent in this population, has been observed to reduce monoclonal antibody affinity in CAR T-cell therapies, potentially contributing to relapse following treatment. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
